Why did PHARM.AS stock fall after hours on 02 Feb 2026?

PHARM.AS stock fell after hours because the FDA issued a Complete Response Letter for the Joenja pediatric sNDA, citing underexposure risk in lower-weight children and an analytical-method issue.

What is Meyka AI's one-year forecast for PHARM.AS stock?

Meyka AI's forecast model projects a one-year price of **€1.99** for PHARM.AS stock, implying about **+38.07%** upside from the current price **€1.439**. Forecasts are projections, not guarantees.

What catalysts should investors watch for PHARM.AS stock?

Watch for Pharming’s request and outcome of a Type A meeting with the FDA, any new pediatric PK or assay data submissions, and the company earnings report on **12 Mar 2026**.

Is PHARM.AS stock a buy after the drop?

Given the regulatory uncertainty, Meyka AI rates PHARM.AS **B / HOLD**. Investors should wait for clarity from the FDA meeting or consider event-driven, risk-managed positions.

EU Stocks

PHARM.AS Pharming Group N.V. EURONEXT -16.58% to €1.44 after hours 02 Feb 2026: FDA CRL

ByHuzaifa Zahoor February 2, 2026February 2, 2026

PHARM.AS stock fell sharply after hours on 02 Feb 2026 after Pharming Group N.V. (PHARM.AS) confirmed an FDA Complete Response Letter tied to its pediatric sNDA for Joenja. The share price traded at €1.44 after hours, a -16.58% move on heavy turnover of 58,182,900.00 shares. Investors focused on dose-exposure data and analytical-method questions from the FDA. This sell-off put PHARM.AS among the most active names on EURONEXT in after-hours trading as market participants reprice regulatory risk and wait for a Type A meeting request